ALAMEDA, Calif.--(BUSINESS WIRE)--Jul. 30, 2009-- InSite Vision Incorporated (OTCBB:INSV) announced today that it will release financial results for the second quarter 2009 on Thursday, August 6, 2009.

Company management will host a conference call beginning at 4:30 PM EDT/1:30 PM PDT to discuss results and review recent accomplishments. Investors can submit questions prior to the conference call via the company's website at: www.insitevision.com through the "Information Request" tab on the Investor Relations page.

Analysts and investors can listen to the conference call by dialing (877) 407-0778 for domestic callers and (201) 689-8565 for international callers. A telephone replay will be available following the conclusion of the call by dialing (877) 660-6853 for domestic callers and (201) 612-7415 for international callers. All callers will need to enter the account number 286 and conference ID 329371.

The live conference call will also be webcast and available on the Investor Relations page of the company's website at www.insitevision.com. A press release detailing second quarter 2009 financial results will also be posted to the company's website and furnished to the Securities and Exchange Commission on a Form 8-K prior to the conference call described above.

About InSite Vision

InSite Vision is committed to advancing new and superior ophthalmologic products for unmet eye care needs. InSite Vision is recognized for the discovery and development of novel ocular pharmaceutical products based on its DuraSite® bioadhesive polymer core technology, an innovative platform that extends the duration of drug delivery on the eye’s surface, thereby reducing frequency of treatment and improving the efficacy of topically delivered drugs. The DuraSite platform is currently leveraged in two products for the treatment of bacterial eye infections, AzaSite® (azithromycin ophthalmic solution) 1% and Besivance™ (besifloxacin ophthalmic suspension) 0.6%. AzaSite is approved in the United States and Canada and currently marketed by InSite Vision’s North American partner, Inspire Pharmaceuticals in the United States. InSite Vision has formed multiple strategic licensing and distribution agreements with qualified partners to market AzaSite in select countries in Europe, Asia and South America upon regulatory approval in those regions. Besivance was approved by the U.S. Food and Drug Administration and launched by Bausch & Lomb and Pfizer Inc. in the second quarter 2009.

InSite Vision’s ophthalmic product development portfolio also includes ISV-502 and additional product candidates leveraging the company’s core technologies. For further information on InSite Vision, please visit www.insitevision.com.

Source: InSite Vision Incorporated

InSite Vision
Chief Executive Officer
Louis Drapeau, 510-747-1220
mail@insite.com
or
Availe Communications
Ellen Rose, 650-387-8746